FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089338169> ?p ?o ?g. }

• W2089338169 endingPage "2268" @default.
• W2089338169 startingPage "2259" @default.
• W2089338169 abstract "A series of quinoline derivatives were analysed for the influence on leukotriene synthesis as a parameter for 5-LOX (EC 1.13.11.34) activity in a cell-free system of the 10,000g supernatant of human PMNL (polymorphonuclear leukocytes). The ratios of the ic50 values for leukotriene synthesis inhibition in this cell-free system and in A23187-stimulated intact PMNL ranged from 1–1100. Consequently, plotting of the two values resulted in a random distribution (r = −0.281, N = 18) suggesting that no relationship between the inhibition of leukotriene synthesis in the cell-free system and in intact cells exists. At first sight this finding was not surprising since we have shown earlier that in intact cells this class of quinoline derivatives shares the same mode of action as MK-886, i.e. an indirect inhibition of 5-LOX activity by binding to FLAP. However, we found that the potency of these compounds in intact cells is strongly influenced by the K value (partition coefficient) which is a parameter for the ability of a substance to accumulate in a lipid (membrane) phase compared to the water phase. Therefore, the ic50 values for leukotriene synthesis inhibition in intact PMNL were corrected for the corresponding K value of the compounds and the resulting values again plotted against the ic50 values for inhibition of leukotriene synthesis in the cell-free system. As a result, a significant correlation (r = −0.878, N = 18) was obtained. In order to simplify this relationship the influence of the partition coefficient was eliminated by comparing compounds with about the same K value (K = 7243 ± 1646, N = 7). As a result, the ic50 values for inhibition of leukotriene synthesis in the 10,000g supernatant fraction (indicative for the affinity of the compounds to 5-LOX) and in intact cells (indicative for the affinity of the compounds to FLAP) were highly, but inversely correlated (r = −0.992). That means that a compound with a high affinity to 5-LOX will have a low affinity to FLAP and vice versa. We hypothesized that this pharmacologically obtained relationship could be indicative of a physiologically occurring equivalent. We therefore propose a model in which FLAP binds arachidonic acid as its physiological substrate with low affinity and allows 5-LOX to get access to its substrate (assuming a higher affinity of 5-LOX to arachidonic acid) after 5-LOX translocation from the cytosol to the membrane. In support of this model we provide evidence that arachidonic acid and other cis-unsaturated fatty acids, but neither a trans-unsaturated nor a saturated fatty acid, inhibit BAY X1005 binding to FLAP in intact human PMNL." @default.
• W2089338169 created "2016-06-24" @default.
• W2089338169 creator A5000919457 @default.
• W2089338169 creator A5014901333 @default.
• W2089338169 creator A5026146238 @default.
• W2089338169 creator A5040038065 @default.
• W2089338169 creator A5068439786 @default.
• W2089338169 creator A5079870410 @default.
• W2089338169 date "1994-06-01" @default.
• W2089338169 modified "2023-09-24" @default.
• W2089338169 title "Inversely-correlated inhibition of human 5-lipoxygenase activity by bay X1005 and other quinoline derivatives in intact cells and a cell-free system—implications for the function of 5-lipoxygenase activating protein" @default.
• W2089338169 cites W1509307264 @default.
• W2089338169 cites W1520264805 @default.
• W2089338169 cites W1528829697 @default.
• W2089338169 cites W1966756382 @default.
• W2089338169 cites W1968575019 @default.
• W2089338169 cites W1978029175 @default.
• W2089338169 cites W1980832959 @default.
• W2089338169 cites W1986305114 @default.
• W2089338169 cites W1999783546 @default.
• W2089338169 cites W2014768234 @default.
• W2089338169 cites W2038575244 @default.
• W2089338169 cites W2051010723 @default.
• W2089338169 cites W2057849240 @default.
• W2089338169 cites W2064700667 @default.
• W2089338169 cites W2065297082 @default.
• W2089338169 cites W2068106905 @default.
• W2089338169 doi "https://doi.org/10.1016/0006-2952(94)90264-x" @default.
• W2089338169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8031320" @default.
• W2089338169 hasPublicationYear "1994" @default.
• W2089338169 type Work @default.
• W2089338169 sameAs 2089338169 @default.
• W2089338169 citedByCount "23" @default.
• W2089338169 countsByYear W20893381692016 @default.
• W2089338169 countsByYear W20893381692018 @default.
• W2089338169 crossrefType "journal-article" @default.
• W2089338169 hasAuthorship W2089338169A5000919457 @default.
• W2089338169 hasAuthorship W2089338169A5014901333 @default.
• W2089338169 hasAuthorship W2089338169A5026146238 @default.
• W2089338169 hasAuthorship W2089338169A5040038065 @default.
• W2089338169 hasAuthorship W2089338169A5068439786 @default.
• W2089338169 hasAuthorship W2089338169A5079870410 @default.
• W2089338169 hasConcept C12554922 @default.
• W2089338169 hasConcept C178790620 @default.
• W2089338169 hasConcept C181199279 @default.
• W2089338169 hasConcept C185592680 @default.
• W2089338169 hasConcept C192552737 @default.
• W2089338169 hasConcept C202751555 @default.
• W2089338169 hasConcept C203014093 @default.
• W2089338169 hasConcept C2776042228 @default.
• W2089338169 hasConcept C2776309666 @default.
• W2089338169 hasConcept C2776452501 @default.
• W2089338169 hasConcept C2776685179 @default.
• W2089338169 hasConcept C2776914184 @default.
• W2089338169 hasConcept C2777752497 @default.
• W2089338169 hasConcept C2778078955 @default.
• W2089338169 hasConcept C2779543280 @default.
• W2089338169 hasConcept C41625074 @default.
• W2089338169 hasConcept C43617362 @default.
• W2089338169 hasConcept C55493867 @default.
• W2089338169 hasConcept C71240020 @default.
• W2089338169 hasConcept C86803240 @default.
• W2089338169 hasConcept C90342290 @default.
• W2089338169 hasConceptScore W2089338169C12554922 @default.
• W2089338169 hasConceptScore W2089338169C178790620 @default.
• W2089338169 hasConceptScore W2089338169C181199279 @default.
• W2089338169 hasConceptScore W2089338169C185592680 @default.
• W2089338169 hasConceptScore W2089338169C192552737 @default.
• W2089338169 hasConceptScore W2089338169C202751555 @default.
• W2089338169 hasConceptScore W2089338169C203014093 @default.
• W2089338169 hasConceptScore W2089338169C2776042228 @default.
• W2089338169 hasConceptScore W2089338169C2776309666 @default.
• W2089338169 hasConceptScore W2089338169C2776452501 @default.
• W2089338169 hasConceptScore W2089338169C2776685179 @default.
• W2089338169 hasConceptScore W2089338169C2776914184 @default.
• W2089338169 hasConceptScore W2089338169C2777752497 @default.
• W2089338169 hasConceptScore W2089338169C2778078955 @default.
• W2089338169 hasConceptScore W2089338169C2779543280 @default.
• W2089338169 hasConceptScore W2089338169C41625074 @default.
• W2089338169 hasConceptScore W2089338169C43617362 @default.
• W2089338169 hasConceptScore W2089338169C55493867 @default.
• W2089338169 hasConceptScore W2089338169C71240020 @default.
• W2089338169 hasConceptScore W2089338169C86803240 @default.
• W2089338169 hasConceptScore W2089338169C90342290 @default.
• W2089338169 hasIssue "12" @default.
• W2089338169 hasLocation W20893381691 @default.
• W2089338169 hasLocation W20893381692 @default.
• W2089338169 hasOpenAccess W2089338169 @default.
• W2089338169 hasPrimaryLocation W20893381691 @default.
• W2089338169 hasRelatedWork W1988889626 @default.
• W2089338169 hasRelatedWork W2009640465 @default.
• W2089338169 hasRelatedWork W2013101996 @default.
• W2089338169 hasRelatedWork W2018430491 @default.
• W2089338169 hasRelatedWork W2020538205 @default.
• W2089338169 hasRelatedWork W2032830404 @default.
• W2089338169 hasRelatedWork W2060605934 @default.
• W2089338169 hasRelatedWork W2089338169 @default.
• W2089338169 hasRelatedWork W2414834571 @default.

• next